A phage barrier for poultry must prove itself on the product, not only in the laboratory

A bacteriophage against *Salmonella* is not yet an automatic commercial solution, but a newly published study provides practical data that justify evaluating the approach in poultry processing. The work characterised phage WP85 against *Salmonella Agona* and applied it to experimentally inoculated chilled chicken meat. At 4 °C, treatment reduced the bacterial population by up to 3.2 log CFU/mL; the authors detected no significant changes in proximate composition, lipid-oxidation indicators or overall meat quality.

The technical basis is particularly relevant. WP85 showed lytic activity against the isolates examined, while the tests reported high stability from 4 to 60 °C, at pH 5–11 and with up to 15% salt. That does not replace industrial validation, but it identifies a candidate capable of tolerating conditions that may arise during formulation, application or storage. The intervention is positioned post-harvest: it is not intended to replace hygiene, temperature control and zone separation, but to add a targeted barrier against a pathogen.

For plants and product developers, the next step must be more demanding than a challenge trial. Dose, spray or dip method, genuine coverage of uneven surfaces, interaction with packaging and performance throughout shelf life need to be tested in defined products and operating lines. Applicable authorisation, safety assessment and a resistance-monitoring strategy are equally necessary. The value of the study is that it combines genomics, stability and testing in a meat matrix—the combination required before a biological promise can become process control.